01533nam a2200229   4500001000700000010001500007090001100022100004100033101000800074200016700082210008300249215001700332330059500349606004900944606002400993606003001017606004101047606001701088710006801105955001101173995011901184384316  a929168063X  a384316  a20070531d1999       y0pory50      ba  aeng  aReport on the risk assessment of MBDB in the framework of the joint action on new synthetic drugsfEuropean Monitoring Centre for Drugs and Drug Addiction, EMCDDA  aLuxembourgcOffice for Official Publications of the European Communitiesd1999  a94 p.d21 cm  aForeword. Abbreviations. Introduction. Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs. Joint action concerning the information exchange, risk assessment and the control of new synthetic drugs. EMCDDA-EDU progress report on the joint action on new synthetic drugs. The pharmacotoxicology and neuropsychology of N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB). Sociological and criminological evidence on the risks of MBDB. Public health risks of MBDB: epidemiological evidence. References. Participants in the risk-assessment process.  aPREVENÇÃO DA TOXICODEPENDÊNCIA9103892  aRELATÓRIO9410454  aDROGA SINTÉTICA9320915  aCOOPERAÇÃO INTERNACIONAL9229150  aOEDT9321506  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION9351987  xOferta  104PJ_19_000000000000000_D_8752022-06-066PJ280889414207aPJcPJfPJ128088kPJ19.D.87n2022-06-06o0rMOxOferta